May 15, 2026 · Phase 3 readout
CODX Phase 3 readout: a negative outcome, -21.2%
On May 15, 2026, Co-Diagnostics, Inc. reached its Phase 3 readout. The result was a negative outcome, and the stock moved -21.2% in the window around the event. It had already run +21.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$1.63
1d before
$1.28
Event day
$1.28
1d after
$2.39
5d after
Our prediction vs. the result
CatalystAlert called this one up (+10.9% expected); the stock actually moved -21.2%. Model confidence at the time: 55%.
See the full scored track recordPre-catalyst setup
+21.1%
30-day run-up
16218%
30-day volatility
0.5×
volume spike